Literature DB >> 14698790

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.

C J Smith1, W A Volkert, T J Hoffman.   

Abstract

The gastrin releasing peptide (GRP) receptor is becoming an increasingly attractive target for development of new radiolabeled peptides with diagnostic and therapeutic potential. The attractiveness of the GRP receptor as a target is based upon the functional expression of GRP receptors in several tumors of neuroendocrine origin including prostate, breast, and small cell lung cancer. This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14698790     DOI： 10.1016/s0969-8051(03)00116-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  17 in total

Review 1.  Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Authors:  Lucia Baratto; Hossein Jadvar; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

2.  Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies.

Authors:  Solveig Schulz; Christoph Röcken; Stefan Schulz
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

3.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

Review 4.  Phage display in molecular imaging and diagnosis of cancer.

Authors:  Susan L Deutscher
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.

Authors:  Hanwen Zhang; Jochen Schuhmacher; Beatrice Waser; Damian Wild; Michael Eisenhut; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-30       Impact factor: 9.236

6.  Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.

Authors:  Christopher V Johnson; Tiffani Shelton; Charles J Smith; Lixin Ma; Michael C Perry; Wynn A Volkert; Timothy J Hoffman
Journal:  Cancer Biother Radiopharm       Date:  2006-04       Impact factor: 3.099

7.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.

Authors:  Adam F Prasanphanich; Prasant K Nanda; Tammy L Rold; Lixin Ma; Michael R Lewis; Jered C Garrison; Timothy J Hoffman; Gary L Sieckman; Said D Figueroa; Charles J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

8.  Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.

Authors:  Jered C Garrison; Tammy L Rold; Gary L Sieckman; Farah Naz; Samantha V Sublett; Said Daibes Figueroa; Wynn A Volkert; Timothy J Hoffman
Journal:  Bioconjug Chem       Date:  2008-08-20       Impact factor: 4.774

Review 9.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

10.  GMP-compliant production of [68Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor.

Authors:  Marc Pretze; Laura Reffert; Steffen Diehl; Stefan O Schönberg; Carmen Wängler; Peter Hohenberger; Björn Wängler
Journal:  EJNMMI Radiopharm Chem       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.